Optimization of T-cell Receptor–Modified T Cells for Cancer Therapy

Component: TCR System (Murine); Description: pmel-1 TCR transgenic T cells — recognize gp100 melanoma antigen in H-2Dᵇ context

Component: TCR System (Human); Description: 1G4 TCR — recognizes NY-ESO-1 (SLLMWITQC) in HLA-A02:01 context

Component: Cytokine Constructs (Murine); Description: SFG retroviral vector with mCD19t (truncated CD19, transduction marker) + either: • mIL12 (IRES; α and β subunit fusion)<br>• mIL18 (P2A self-cleaving peptide; mature form)

Component: Cytokine Constructs (Human); Description: SFG retroviral vector with 1G4 TCR α/β chains + equine 2A + signal peptide + mature hIL18

Component: Tumor Models; Description: • Syngeneic: C57BL/6 mice; B16F10 melanoma (gp100⁺, CD80/86⁻)<br>• Xenograft: NSG mice; A375 human melanoma (HLA-A2⁺, NY-ESO-1⁺)

Component: Host Models; Description: • Wild-type C57BL/6<br>• CD80/86⁻/⁻ (costimulation-deficient)<br>• IL18R⁻/⁻ (for cis vs. trans experiments)<br>• pmel-1 × IL18R⁻/⁻ donor T cells

Component: Transduction; Description: Retroviral spinoculation (Phoenix-ECO for murine; 293 galv9 for human); RetroNectin plates

Component: Preconditioning; Description: 5 Gy total body irradiation (sublethal)

Component: Dosing; Description: • Murine: 5×10⁶ T cells i.v.; weekly ×3 or single infusion<br>• Human: 2.5×10⁶ T cells i.v.; single infusion

Parameter: In Vitro Studies; Details: • Cytokine secretion (Luminex)<br>• Cytotoxicity: luciferase-based killing assay (24 h)<br>• CD25 expression (flow cytometry)<br>• IFNγ secretion (ELISA/Luminex)

Parameter: In Vivo Syngeneic Model; Details: B16F10 s.c. (day -10); T cell infusion (day 0, 7, 14); tumor volume measured; survival monitored; endpoint >1,000 mm³

Parameter: Irradiation Studies; Details: 5 Gy total body irradiation (day -1); single T cell infusion (day 0) or weekly ×3

Parameter: Tumor Microenvironment Analysis; Details: Tumor dissociation; flow cytometry: CD206⁺ M2 macrophages, Gr1⁺ MDSCs, CD11c⁺MHCII⁺ DCs, Thy1.1⁺ pmel-1 T cells; day 6 and 13 post-infusion

Parameter: Ex Vivo T Cell Function; Details: FACS-sorted Thy1.1⁺ T cells; coculture with B16F10 GFP/luc; IFNγ secretion (Luminex); cytotoxicity (luciferase loss)

Parameter: Cis vs. Trans Experiment; Details: pmel-1⁺/⁺ IL18R⁻/⁻ donor T cells; C57BL/6 or IL18R⁻/⁻ hosts; assess tumor growth and survival

Parameter: Human Xenograft Model; Details: NSG mice; A375 s.c. (day -10); 1G4 or 1G4hIL18 T cells (day 0); peripheral blood T cell counts (day 7); tumor volume and survival

Parameter: Controls; Details: mCD19t-only T cells (murine); mock-transduced T cells (human); no T cell control

Parameter: Sample Sizes; Details: n=4-17 per group (as indicated)

Parameter: Statistical Tests; Details: Unpaired two-tailed t-test; one-way/two-way ANOVA; Mann-Whitney (tumor volume); log-rank (survival); P<0.05 significant

Analysis Category: Cytokine Secretion; Methods: Luminex (Millipore; FlexMap3D); IFNγ, IL2, IL12, IL18, TNFα, IL6, IL10

Analysis Category: Cytotoxicity; Methods: Luciferase-based killing assay (Spark plate reader); % lysis = [1 - (sample/max)] × 100

Analysis Category: Flow Cytometry; Methods: Gallios (10-color) or Attune NxT (14-color); antibodies for mouse (CD3, CD4, CD8, CD44, CD62L, CD25, PD-1, TIM-3, LAG-3, CD80, CD86, CD206, Gr-1, CD11b, CD11c, MHCII, Thy1.1, FoxP3, IL18R) and human (CD3, CD4, CD8, CD80, CD86, HLA-A2, NY-ESO-1 tetramer); DAPI or LIVE/DEAD for viability; 123count eBeads for quantification

Analysis Category: T Cell Persistence; Methods: Flow cytometry: Thy1.1⁺ pmel-1 T cells in tumor, spleen, blood; human 1G4 T cells in peripheral blood

Analysis Category: Intracellular Staining; Methods: Foxp3/Transcription factor staining buffer set (eBioscience)

Analysis Category: Serum Analysis; Methods: Retro-orbital bleeds; serum cytokines by Luminex

Analysis Category: Ex Vivo T Cell Function; Methods: FACS sorting of Thy1.1⁺ T cells from tumors; coculture with B16F10; IFNγ secretion; cytotoxicity

Parameter: IFNγ secretion; Control: Baseline; mIL12 pmel-1: Significantly increased; mIL18 pmel-1: Significantly increased

Parameter: CD25 expression; Control: Baseline; mIL12 pmel-1: ↑; mIL18 pmel-1: ↑

Parameter: Cytotoxicity (vs. B16F10); Control: Low; mIL12 pmel-1: Highest; mIL18 pmel-1: Intermediate (enhanced vs. control)

Parameter: Tumor growth delay; Control: Minimal; mIL12 pmel-1: Significant; mIL18 pmel-1: Most significant

Parameter: Overall survival; Control: Baseline; mIL12 pmel-1: Enhanced; mIL18 pmel-1: Significantly enhanced vs. mIL12

Parameter: CD206⁺ M2 macrophages in tumor; Control: High; mIL12 pmel-1: Reduced; mIL18 pmel-1: Fewest

Parameter: Gr1⁺ MDSCs; Control: High; mIL12 pmel-1: Reduced; mIL18 pmel-1: Significantly reduced

Parameter: CD11c⁺MHCII⁺ DCs; Control: Low; mIL12 pmel-1: Moderate; mIL18 pmel-1: Significantly increased

Parameter: Thy1.1⁺ pmel-1 T cells in tumor; Control: Low; mIL12 pmel-1: Moderate; mIL18 pmel-1: Highest accumulation

Parameter: Thy1.1⁺ T cell accumulation; Day 6: mIL18 > mIL12 = control; Day 13: mIL18 only maintained

Parameter: PD-1⁺ (activation); Day 6: All groups; Day 13: All groups

Parameter: PD-1⁺TIM-3⁺LAG-3⁺ (dysfunction); Day 6: mIL12 highest; Day 13: mIL18 lowest

Parameter: IFNγ secretion; Day 6: mIL12 & mIL18 enhanced; Day 13: mIL18 only maintained

Parameter: Cytotoxicity; Day 6: mIL12 & mIL18 enhanced; Day 13: mIL18 only maintained

Parameter: Tumor growth; Control: Rapid; mIL12 pmel-1: Delayed; mIL18 pmel-1: Most delayed (comparable to WT)

Parameter: Survival; Control: Baseline; mIL12 pmel-1: Enhanced; mIL18 pmel-1: Significantly enhanced

Parameter: Tumor eradication; Control: None; mIL12 pmel-1: Toxicity (100% mortality); mIL18 pmel-1: 8/9 (88.8%) cured

Parameter: Serum IL12; Control: Low; mIL12 pmel-1: Extremely high; mIL18 pmel-1: Low

Parameter: Serum IFNγ, TNFα, IL6, IL10; Control: Low; mIL12 pmel-1: Extremely high (cytokine storm); mIL18 pmel-1: Elevated (tolerated)

Parameter: Tregs in tumor; Control: Present; mIL12 pmel-1: -; mIL18 pmel-1: Significantly reduced

Parameter: Granulocytic MDSCs; Control: Present; mIL12 pmel-1: -; mIL18 pmel-1: Significantly reduced

Parameter: Thy1.1⁺ pmel-1 T cells; Control: Low; mIL12 pmel-1: -; mIL18 pmel-1: Highest

Donor T Cells: pmel-1 (IL18R⁺); Host: WT; mIL18 Effect: Survival enhanced

Donor T Cells: pmel-1 (IL18R⁺); Host: IL18R⁻/⁻; mIL18 Effect: Survival enhanced

Donor T Cells: pmel-1 × IL18R⁻/⁻; Host: WT; mIL18 Effect: No survival benefit

Donor T Cells: pmel-1 × IL18R⁻/⁻; Host: IL18R⁻/⁻; mIL18 Effect: No survival benefit

Donor T Cells: Conclusion; Host: IL18 acts in cis (on adoptively transferred T cells)

Parameter: hIL18 secretion; Mock: None; 1G4: None; 1G4hIL18: Significant

Parameter: IFNγ secretion; Mock: Baseline; 1G4: Enhanced; 1G4hIL18: Enhanced

Parameter: IL2 secretion; Mock: Baseline; 1G4: Enhanced; 1G4hIL18: Enhanced

Parameter: Cytotoxicity (vs. A375); Mock: Low; 1G4: Enhanced; 1G4hIL18: Enhanced

Parameter: T cell persistence in blood (day 7); Mock: Low; 1G4: Moderate; 1G4hIL18: Highest

Parameter: Tumor growth (A375 xenograft); Mock: Rapid; 1G4: Delayed; 1G4hIL18: Most delayed

Parameter: Overall survival; Mock: Baseline; 1G4: Enhanced; 1G4hIL18: Significantly enhanced

1. Model antigen and tumor systems: The study uses model antigens (gp100, NY-ESO-1) and established cell lines; efficacy against patient-derived tumors or neoantigens was not tested.

2. Constitutive cytokine expression: IL18 was expressed constitutively from the LTR promoter, not under an inducible system. While no toxicity was observed in immune-competent mice, long-term safety of constitutive IL18 secretion remains to be established.

3. IL12 toxicity with preconditioning: IL12-secreting T cells were toxic only when combined with irradiation; the study did not explore lower doses of IL12 or more controlled expression systems.

4. Human xenograft model limitations: NSG mice lack a functional immune system; the human system studies did not assess effects on endogenous immune cells, and human T cells were not tested in immunocompetent models.

5. No direct comparison of IL18 vs. IL12 in human system: The human studies only tested IL18; IL12 was not tested in the 1G4 system, limiting direct translational comparison.

6. No assessment of tumor antigen escape or recurrence: Long-term follow-up beyond the study endpoint was not reported; potential for antigen loss variants was not evaluated.

7. Cytokine receptor expression not fully characterized: While IL18R expression was confirmed on pmel-1 T cells, the study did not comprehensively characterize IL18R expression on different T cell subsets or over time after adoptive transfer.

8. Single tumor model per system: Only B16F10 (melanoma) for murine and A375 (melanoma) for human; efficacy in other tumor types was not demonstrated.

9. No evaluation of IL18 on Tregs: IL18 can affect Treg function; this was not extensively characterized.

10. Ex vivo analyses limited to two time points: Day 6 and day 13 were the only time points examined; the kinetics of T cell persistence and dysfunction between these time points were not fully mapped.

11. Preconditioning regimen not optimized: Only one irradiation dose (5 Gy) was tested; dose-response and other lymphodepleting regimens were not explored.

12. No in vivo imaging: T cell trafficking and tumor localization were inferred from tumor digestion, not directly visualized.

Report prepared based on the published Cancer Immunology Research article. For full experimental details, supplementary figures, and complete references, please refer to the original publication.